This therapeutic concept has been investigated in AML exclusively in preclinical models, using combinations such as CD93/CD19-iCAR, CD33/HLA-DR-iCAR, CD15-iCAR/CLEC12A, and CD16-iCAR/CLEC12A [35,36,37]. The gene discussed is CD33; the disease is acute myeloid leukemia.